Crimean-Congo Hemorrhagic Fever in Turkey by Karti, S. Sami et al.
In 2002 and 2003, a total of 19 persons in Turkey had
suspected cases of Crimean-Congo hemorrhagic fever
(CCHF) or a similar viral infection. Six serum samples were
tested; all six were found positive for immunoglobulin M
antibodies against CCHF virus. Two of the samples yielded
CCHF virus isolates. Genetic analysis of the virus isolates
showed them to be closely related to isolates from former
Yugoslavia and southwestern Russia. These cases are the
first of CCHF reported from Turkey. Eighteen patients han-
dled livestock, and one was a nurse with probable nosoco-
mial infection. The case-fatality rate was 20% among
confirmed CCHF case-patients (1 of 5 patients), and the
overall case-patient fatality rate was 11% (2 of 19 patients).
In addition to previously reported symptoms and signs, we
report hemophagocytosis in 50% of our patients, which is
the first report of this clinical phenomenon associated with
CCHF. 
C
rimean-Congo hemorrhagic fever (CCHF) is an acute
illness affecting multiple organ systems and character-
ized by extensive ecchymosis, visceral bleeding, and
hepatic dysfunction; and it has a case-fatality of 8% to
80% (1). CCHF virus (CCHFV) (genus Nairovirus, family
Bunyaviridae) is transmitted to humans by bites of infect-
ed ticks (several species of genus Hyalomma). CCHFV has
also been transmitted to patients or viremic livestock
through contact with blood or tissue (1). Epidemics of
CCHFV have previously been reported from Eastern
Europe, Africa, and central Asia (2–8). Many cases have
been reported from the countries around Turkey, including
Albania, Iran, Iraq, Russia, and the former Yugoslavia
(7,9–12). Although serologic evidence indicated the exis-
tence of CCHFV in Turkey several decades ago (13), no
clinical cases have been documented. We describe 19
patients from the eastern Black Sea region with hemor-
rhagic fever compatible with CCHF, who were admitted to
Karadeniz Technical University Hospital during the spring
and summer of 2002 and 2003.
Patients and Methods
Patients
Several patients in May through July 2002 and 2003
were referred from surrounding county hospitals to our
hematology unit with varying degrees of fever and hema-
tologic manifestations. All of the patients had similar clin-
ical and laboratory findings, including fever, petechiae,
headache, abdominal pain, nausea, vomiting, liver enzyme
elevations, and cytopenia. Bone marrow aspiration and
routine serologic tests excluded hematologic malignancies
and known viral or bacterial infections. Serum samples
from several patients admitted in 2003 were stored at
–80°C for further diagnostic testing for a possible hemor-
rhagic fever agent.
Laboratory Testing
Serum samples from seven patients were sent to Special
Pathogens Branch, Centers for Disease Control and
Prevention, Atlanta, GA (CDC) for testing. Only six sam-
ples from five patients were available in sufficient volume.
After we considered possible hemorrhagic fever viruses in
the region, we performed immunoglobulin (Ig) M and IgG
enzyme-linked immunosorbent assay (ELISA), using inac-
tivated native CCHFV (Strain IbAr 10200) antigens grown
in Vero E6 cells on serum samples (14). Atest developed to
detect CCHF viral antigens was also performed (15). Virus
isolation attempts from the serum samples were conducted
under biosafety level 4 conditions with Vero E6 cells. 
For virus genetic detection and analysis, serum samples
or infected Vero E6 cells were combined with Tripure
Isolation Reagent (Roche Applied Science, Indianapolis,
IN) in a ratio of 1:5 and incubated at room temperature for
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Georgia,  USAa minimum of 10 min. Total RNA was isolated by using
the RNaid Kit following manufacturer’s recommendations
(Qbioene Inc., Carlsbad, CA), and the extracted RNA was
resuspended in 50 µLH 2O. Five microliters of the RNA
was used in a 50-µL reverse transcription (RT) reaction
with the Access RT-PCR System (Promega Biosciences,
San Luis Obispo, CA). The primers that enabled the ampli-
fication of nucleocapsid-coding sequence (S segment)
were previously described as was the polymerase chain
reaction (PCR) method used, with slight modifications
(16). Briefly, separate RT was performed by using CCHF-
F2 primer at 42°C for 1 h. Ten microliters of the RT reac-
tion was subsequently used in a 50-µL PCR reaction with
FastStart Taq DNA Polymerase with GC-rich solution
(Roche) and primers CCHF-F2 and CCHF-R3. The tem-
perature profile for the PCR reaction was as follows: 2 min
at 95°C (36 cycles of 1 min at 95°C and 1 min at 45°C), 2
min at 72°C, and a final elongation of 10 min at 72°C.
Amplified DNA was analyzed by using a 1% low-melt
agarose gel, and bands corresponding to 536-bp products
were purified by using the Qiagen Gel Extraction Kit
(Qiagen, Valencia, CA). Sequencing of both DNA strands
was performed by using primers CCHF-F2 and CCHF-R3
in a BigDye Terminator v3.1 reaction on the 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA). The
obtained sequences were analyzed with Sequencer (Gene
Codes Corporation, Ann Arbor, MI).
Results
Serologic test results for hepatitis A, B, and C viruses
(HAV, HBV, and HCV); herpes viruses; and HIV and PCR
for HBV DNA and HCV RNA were negative. Although
malaria does not exist in these provinces, peripheral blood
smear examinations confirmed these specimens to be neg-
ative for Plasmodium. Bacterial blood cultures were nega-
tive in all patients. Serologic tests for Brucella and
Leptospira were also negative in all patients. Samples
were negative for anti-Alkhurma virus IgM, and IgG.
Specific testing for CCHFV antigen detection, IgG and
RT-PCR tests were negative for the six specimens from the
five patients. However, all six specimens were positive for
IgM antibodies reactive with CCHFV antigen. CCHFV
(CDC, Special Pathogens numbers: 200310845 and
200310849) were isolated from two of the patients. 
RT-PCR products of the correct predicted size (536 bp)
were obtained for each of the viruses and sequenced. The
resulting nucleotide sequences had high identity with pre-
viously characterized CCHFV strains, and 11 nucleotide
differences were detected between the virus sequences
obtained from the two patients. Comparison of the
deduced amino acid sequences indicated that no amino
acid differences existed between the two virus strains.
Detailed genetic comparison was performed by using the
CCHFV S segment sequences available from GenBank.
The analysis indicated the close relatedness of the Turkish
CCHFV isolates to CCHFV strains from Russia and
Kosovo, with 97%–98% and 100% identity at the
nucleotide and protein levels respectively (data not
shown). Acomprehensive phylogenetic analysis (Figure 1)
by using PILEUP (Wisconsin Package Version 10.2,
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Figure 1. Phylogenetic analysis of Crimean-Congo hemorrhagic
fever virus (CCHFV) genetic difference. Maximum parsimony
analysis of the aligned sequences of a 488-nt region of CCHFV S
segments and the equivalent genome region of Dugbe and Nairobi
sheep disease viruses. Analysis was performed with the heuristic
search method with stepwise addition, tree bisection-reconnection
branch swapping, and transversions; transitions were weighted
4:1. The graphic representation of the results was outgroup rooted
by using the Dugbe (GenBank accession no. AF434161,
AF434162, AF434163, AF014014, AF434164, AF014015,
AF434165) and Nairobi sheep disease virus (AF504293) S seg-
ment nucleotide sequences. The node attaching the outgroup to
the CCHFV tree topology is shown by the arrow at the base of the
tree. Horizontal distances within the CCHFV part of the tree are
proportional to nucleotide steps (see scale bar), separating virus
taxa and nodes. Vertical and diagonal lines are for visual clarity.
Each virus sequence is indicated by the corresponding GenBank
accession number. The two CCHFV sequences are in bold.Genetics Computer Group, Inc.), followed by
PAUP4.0b10 (Sinauer Associates Inc., Sunderland, MA,
USA), showed that the Turkish CCHFV isolates clustered
closely with the CCHFV strains from southwest Russia
and Kosovo. Bootstrap analysis showed the clade contain-
ing the Russian, Balkan, and Turkish CCHFV to be well
supported (99%), and these viruses are clearly distinct
from those in other virus clades, including the clade con-
taining the CCHFV detected in the CCHF outbreak in
neighboring Iran in 2002 (GenBank accession no.
AY366373–9).
Nineteen patients (including the five laboratory-con-
firmed patients) who fulfilled suspected-case criteria for
CCHF of the European Network for Diagnostics of
Imported Viral Diseases (ENIVD) were identified in 2002
and 2003 (17). Nine patients were admitted from May
through July 2002, and 10 patients were admitted in June
to July 2003. Most of the patients were female (15 female
vs. 4 male), and the mean age was 42 ± 8 year. Twelve of
19 patients were from Gumushane, and the other 7 were
from the neighboring cities of Giresun (4 patients), Artvin
(2 patients), and Trabzon (1 patients) (Figure 2). All of
them, except one, handled livestock; none of the patients
described tick bites. However, six patients gave a history
of removing ticks from livestock. The remaining patient
was a nurse in a county hospital in Trabzon. Signs and
symptoms observed in the patients are shown on the Table.
The most commonly encountered signs and symptoms
were malaise, fever, abdominal pain, myalgia, nausea,
vomiting, petechiae, and bleeding from gingiva, nose,
vagina, or gastrointestinal system. Complete blood counts
showed thrombocytopenia in all patients (median 15 x
103/µL, range: 1–87 x 103/µL), leukopenia in 15/19 (medi-
an 1,700/µL, range 700–5,200/µL), and anemia in 5 of 19
patients (median 13.8g/dL, range 6.1–17.3 g/dL). Serum
aspartate aminotransferase (AST) (median 693 U/L, range
178–5,220U/L), alanine aminotransferase (ALT) (median
248 U/L, range 66–1,438 U/L), and lactate dehydrogenase
(LDH) (median 1,601 U/L, range 650–20,804 U/L) levels
were elevated in all patients. Coagulation tests showed
prolonged prothrombin time (PT) (median 13.4 s, range
12.1–18.5 s) and activated partial thromboplastin time
(aPTT) (median 34.9 s, range 30.2–59.1 s) in 7 of 19
patients. Fibrinogen was decreased and D-dimer was ele-
vated in one patient with suspected CCHF, which indicat-
ed disseminated intravascular coagulation. Fibrinogen and
D-dimer levels were normal in other patients. Creatine
phosphokinase (CPK) levels were elevated in 14 of 19
patients (median 568 U/L, range 81–2,500 U/L). Blood
urea nitrogen and creatinine (median 0.8 mg/dL, range
0.5–6.2 mg/dL) were found to be elevated in 2 of 19
patients. Hematologic malignancies were excluded after
bone marrow aspiration smear and trephine biopsy in 14
patients. In 7 of 14 patients (including 2 of 5 confirmed
patients), hemophagocytosis with proliferation of histio-
cytes in bone marrow smears was present (Figure 3).
All patients received intensive clinical supportive
measures, including platelets, fresh frozen plasma, and
packed erythrocyte infusions, when indicated. Despite
supportive treatment, one confirmed and one suspected
CCHF patient died. The suspected CCHF patient was a
nurse who had a history of taking care of similar clinical
patients in a county hospital in Trabzon. She died of
intraabdominal and pulmonary hemorrhage. The other
patient died of massive gastrointestinal bleeding. The
remaining 17 patients recovered within 5 to 10 days with
clinical supportive measures.
Discussion
CCHF was first described in Crimea in 1944. In 1969,
the pathogen that caused the disease was recognized to be
the one responsible for febrile illnesses identified in the
Congo. Since then, many human cases have been reported
from different regions, namely Zaire, Uganda, Saudi
Arabia, United Arab Emirates, Pakistan, European Russia,
Iran, and South Africa (2–9). Additionally, sporadic cases,
as well as large outbreaks, were reported from various
regions, such as Kosovo and Kenya (10,12,18). Neither
sporadic cases nor outbreaks have been previously report-
ed from Turkey. All of the five patients’ serum samples
tested were found to be positive for IgM antibodies for
CCHFV. Findings from the RT-PCR, antigen detection,
and IgG tests were negative. These findings are in accor-
dance with recent infection with CCHFV in these five
patients. The negative RT-PCR findings are in accordance
with the presence of IgM in all the samples; we usually
find that we cannot detect infectious virus or virus RNA
once detectable antibody has developed. Nevertheless, on
this occasion, we were able to isolate CCHFV from two of
the patients. IgM and IgG antibodies are usually not
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Figure 2. Geographic distribution of patients with Crimean-Congo
hemorrhagic fever (CCHF), Turkey, 2002–2003. Residency of the
patients with CCHF infection from our series is marked in the cir-
cle. Epicenter of a concurrent outbreak presented at the recent
conference in Ankara is shown as a rectangle.detectable in early phase of illness, and they usually begin
to rise during day 7–10 of infection. During the early
phase, antigen detection and RT-PCR are usually the tests
of choice for a sensitive laboratory diagnosis (19). All the
patients were referred to our clinic, and blood samples
were drawn >1 week after onset of illness.
These CCHF cases are among the first documented in
Turkey. Similar cases have been reported in other
provinces of eastern Turkey. Tokat, Yozgat, and Sivas
seem to be the epicenter of the outbreak (Turkish Society
of Clinical Microbiology and Infectious Diseases, unpub.
data) (Figure 2). The cases in those areas are the subject of
ongoing epidemiologic studies. No deaths were observed
among the suspected CCHF patients during 2002; 2 of the
10 patients in the 2003 outbreak died of extensive visceral
hemorrhages. One of the patients was a nurse in the emer-
gency clinic of a local hospital with a possible exposure to
a suspected CCHF patient. Nosocomial transmission of
CCHFV through infected blood or body secretions from
patients has been reported many times in the literature
(12,20–22). The exact procedures performed by the nurse
are not clear. She likely had an exposure to blood or infect-
ed body fluids of viremic patients affected by an unknown
disease in the region. All the other patients handled live-
stock. In the eastern Black Sea region, women carry out
most of the livestock handling, which may explain why
most of the patients were female. Handling CCHF-infect-
ed animal materials, such as milk and meat, is a recognized
means of infection (19) and the probable means of infec-
tion for most of our patients, since none had a reported his-
tory of tick bite. Some of our patients also gave a history
of removing ticks from livestock, and this behavior has
been incriminated in CCHF infections. 
The most common clinical signs and symptoms report-
ed in CCHF are fever, myalgia, dizziness, malaise, back-
ache, headache, photophobia, nausea, vomiting, diarrhea,
abdominal pain, petechiae, ecchymosis, and visceral
bleeding. Most of these signs and symptoms were also
observed in our patients. We observed elevated CK levels
in 14 (75%) of 19 patients, including all of the confirmed
CCHF patients. Elevated CK values can be explained with
myositis, but the pathologic findings do not demonstrate
myositis in the literature, and we did not have muscle biop-
sies from our patients. Rhabdomyolysis could be another
explanation for elevated CK values, but urine samples
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Table. Signs and symptoms among clinically suspected and confirmed CCHF patients
a 
Signs and symptoms   Confirmed cases n  = 5  Suspected cases n  = 14  Total (%) n = 19 
Malaise  5  14  19 (100) 
Fever  4  12  16 (84) 
Nausea and vomiting    3  13  16 (84) 
Abdominal pain   3  13  16 (84) 
Petechiae-ecchymosis  5  6  11 (58) 
Myalgia  4  4  8 (42) 
Bleeding from various sites   1  7  8 (42) 
Diarrhea  3  4  7 (37) 
Lymphadenopathy   1  3  4 (21) 
Hepatomegaly  1  3  4 (21) 
aCCHF, Crimean -Congo hemorrhagic fever.  
 
Figure 3. Bone marrow aspiration smear, stained with Wright,
showing hemophagocytosis. A) phagocytosis of an erythrocyte
and nuclear remnants by a macrophage. B) shows phagocytosis
of platelets by a macrophage.were also not tested for myoglobinuria. Among those
patients with high CK levels, two had acute renal failure.
Elevated CK values have also been reported in some other
clinical series (23). 
Hemophagocytosis, which has not been reported previ-
ously in CCHFV infections, was also found in our patients.
This condition can develop secondary to many viral, bac-
terial, fungal, parasitic, and collagen vascular diseases
(24). We detected reactive hemophagocytosis in 7 (50%)
of 14 patients, which suggested that hemophagocytosis can
play a role in the cytopenia observed during CCHF infec-
tion. Varying degrees of cytopenia are consistently found
in CCHF infection (23), but to our knowledge, this is the
first study demonstrating hemophagocytosis in CCHF
patients. Only two case reports demonstrate hemophago-
cytosis with Hantaan and Puumala viruses (genus
Hantavirus) among all the hemorrhagic fever viruses
(25,26). Excessive activation of monocytes attributable to
stimulation by high levels of Th1 cytokines, such as inter-
feron-γ, tumor necrosis factor-α, interleukin (IL)-1 or IL-
6, are proposed as possible immunopathologic mechanism
of hemophagocytic lymphohistiocytosis (24). Cytokine
studies are lacking in CCHFV infection and are needed for
a better understanding of pathogenesis of the disease
caused by CCHFV.
Prolongation of PT and PTT was thought to be caused
by liver damage. However, in one of our patients, dissem-
inated intravascular coagulation was clearly demonstrated.
That patient was the nurse who died with pulmonary and
intraabdominal bleeding. Contributing disseminated
intravascular coagulation may be associated with a poor
prognosis in CCHF infection. Although disseminated
intravascular coagulation has been reported previously in
some CCHF cases, the exact mechanism for hemorrhage
remains unknown (23,27). Of the viral hemorrhagic fevers,
CCHF infection has the most florid hemorrhage and high-
est frequency of large ecchymoses. Besides elevated PT,
aPTT, and thrombocytopenia, damage to vascular endothe-
lium directly by the virus can lead to bleeding tendencies
(27,28). 
Overall laboratory findings in our patients were consis-
tent with the findings in other CCHF case series. Liver
transaminase levels were high in our patients, and AST
values were generally higher than ALT values, probably
attributable to concomitant muscle damage. Beside the
hepatic vascular involvement and resulting infarctions in
liver parenchyma, direct hepatocellular involvement may
also be responsible for elevated serum aminotransferases
(23,27). 
Any of the following clinical pathologic values during
the first 5 days of illness were found to be >90% predictive
of fatal outcome in a series of South African CCHF
patients: leukocyte counts <10 x 109/L, platelet counts <20
x 109/L, AST >200 U/L, ALT >150 U/L, aPTT >60 s, and
fibrinogen <110 mg/L (23). Although most of our patients
have at least one or more of the risk factors described
above, the overall death rate was low at 11%. Although
very high death rates are reported in some series, low death
rates in our patients can be explained with better support-
ive care of the patients. Regional strain differences in
CCHFV may also play a role in the differential death rates.
Phylogenetic analysis of virus sequence differences
indicates that at least two different genetic lineages of
CCHFV are circulating within this current Turkish out-
break. These closely resemble virus lineages found in
Kosovo and southwestern Russia and are clearly distinct
from those associated with the recent CCHF outbreak in
Iran in 2002 (9). The data are most consistent with CCHF’s
being enzootic in the affected areas in Turkey, rather than
having been introduced from Iran by infected tick or live-
stock movement. The virus might also have come from
Russia by birds migrating with their ticks across the Black
Sea. Turkey is known to be on the flight path of some birds
migrating from Russia to Africa during the winter.
However, a number of recognized tick vectors and reser-
voirs have been known to occur in the region for many
years (29), and serologic data from several decades in the
past support the previous existence of the virus as well (13).
Our patients are among the first with documented cases
of CCHFV infection in Turkey. Recognition of dozens of
cases in many provinces of Eastern Turkey during the last
2 years led to the awareness of a previously unrecognized
illness in the region. In addition, we documented, for the
first time, the occurrence of reactive hemophagocytic syn-
drome in CCHFV infection, which may be responsible for
some of the clinical manifestations. Tick bite, occupation-
al exposure to the virus from infected animals, and noso-
comial exposure to patients appear to have been the major
transmission routes in this outbreak.
Dr. Karti is a hematologist with Karadeniz Technical
University, School of Medicine. His research interests include
nonmalignant hematology and chronic myeloid leukemia.
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